Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">Cytokinetics initiated with a Buy at Rodman & Renshaw; tgt $25 (11.50)Rodman & Renshaw initiates CYTK with a Buy and price target of $25. Firm believes CYTK represents a core long-term holding for investors. Co has strong clinical data in hand for its two lead assets (omecamtiv mecarbil and tirasemtiv), two pharma partners, strong cash, and has reached a critical execution phase in co's history, in their view. The valuation of omecamtiv mecarbil alone warrants purchasing the shares, in their belief.</td> </tr></table>"